The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases
Open accessAbstract
Recently, adeno-associated virus (AAV)-mediated gene therapies have attracted clinical interest for treating neurodegenerative diseases including spinal muscular atrophy (SMA), Canavan disease (CD), Parkinson’s disease (PD), and Friedreich’s ataxia (FA). The influx of clinical findings led to the first approved gene therapy for neurodegenerative disorders in 2019 and highlighted new safety concerns for patients. Large doses of systemically administered AAV stimulate host immune responses, resulting in anti-capsid and anti-transgene immunity with implications for transgene expression, treatment longevity, and patient safety. Delivering lower doses directly to the central nervous system (CNS) is a promising alternative, resulting in higher transgene expression with decreased immune responses. However, neuroinflammatory responses after CNS-targeted delivery of AAV are a critical concern. Reported signs of AAV-associated neuroinflammation in preclinical studies include dorsal root ganglion (DRG) and spinal cord pathology with mononuclear cell infiltration. In this review, we discuss ways to manage neuroinflammation, including choice of AAV capsid serotypes, CNS-targeting routes of delivery, genetic modifications to the vector and/or transgene, and adding immunosuppressive strategies to clinical protocols. As additional gene therapies for neurodegenerative diseases enter clinics, tracking biomarkers of neuroinflammation will be important for understanding the impact immune reactions can have on treatment safety and efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TLR2 detects the capsid proteins of extracellular viral particles, while TLR9 detects unmethylated CpG motifs within single-stranded viral DNA genomes present in endosomes (Perez et al., 2020; Wright, 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Perez et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, targeting the CNS through systemic administration remains challenging and requires vector doses 10-to 100-times higher than those used to target the liver 2,3 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“since various AAV vectors themselves can increase both astrocytic and microglial markers (Ciron et al., 2006; Perez et al., 2020)”
From The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease (2022) · cites this paper as Perez et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688 · cited 9×
“IT delivery of AAV is being tested across several clinical trials for SMA (NCT03381729), GAN (NCT03770572), MPS II (NCT0356604), and others.”
ResultInfluentialRetractedGlutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Similarly, differences in blood-brain barrier permeability between healthy animals and models of neurodegenerative diseases could result in different AAV biodistribution in the CNS, possibly contributing to discrepancies in translating findings from mouse models of disease into toxicology studies using larger, healthy…”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 3×
“Similarly, several preclinical studies and clinical trials [5,42] evaluated safety and efficacy data with no significant findings in support of the U.”
BackgroundManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“Although the overall immunogenicity of AAV-based gene therapies is well characterized [6,7,9], immunogenicity from CNS-directed AAV delivery has not been widely investigated.”
BackgroundHow neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967 · cited 1×
“Neuroinflammation is already a feature of many neurodegenerative diseases such as AD, Parkinson’s disease (PD), and multiple sclerosis (MS) [27].”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“In 2002, AAV 7, 8, 9 and rh10 were discovered in primates [55].”
BackgroundIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“Of the common capsids currently available, AAV9 has emerged as the most widely used for CNS gene therapy applications due to its enhanced spread across CNS structures and its ability to penetrate the BBB even after peripheral administration in neonatal animals [61,62].”
BackgroundHumoral Immunity Due to Long-Lived Plasma Cells
Slifka, M. K., Antia, R., Whitmire, J. K., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80541-5 · Cited by 1,245 · cited 1×
“In addition to managing systemically circulating antibodies, difficult to eliminate long-lived plasma cells may be reactivated by AAV treatment, secreting additional antibodies [97,98].”
Background
Research works printed but not linked: 9
- Corti, M., Norman, S., Coleman, K., Liberati, C., Elder, M., Escolar, M., Clement, N., Clever, B., Byrne, B., and Gao, G. (2018). Immune Blockade in CNS Gene Therapy Improves Safety and Clinical Outcome, Cell Press. Molecular Therapy.
- Nair, J., Freeman, D., Davis, I., McParland, T., Pope, M., Perez, B., Rodriguez-Lebron, E., Coleman, K., Subramony, S., and Byrne, B. (2019). AAV9 Biodistribution with Different Routes of CNS Administration in Rodents, Cell Press. Molecular Therapy.
- Perez, B.A., Coleman, K.E., Wichman, M.B., Futch, K.N., Mandolini, K.E., Cravey, L.D., Nair, J., Cloutier, D.A., Lynch, D., and Byrne, B.J. (2019). Management of Preexisting Immunity to AAV9 in Friedreich’s Ataxia, Cell Press. Molecular Therapy.
- Letizia, A., Chan, Y.K., Graveline, A., and Church, G. (2019). Engineering AAV Vectors to Reduce CD8+ T Cell Responses Following Intramuscular Injection in Mice, Cell Press. Molecular Therapy.
- Chan, Y.K., Wang, S., Letizia, A., Chan, Y., Lim, E., Graveline, A., Verdera, H.C., Alphonse, P., Xue, Y., and Chiang, J. (2019). Reducing AAV-Mediated Immune Responses and Pathology in a Subretinal Pig Model by Engineering the Vector Genome, Cell Press. Molecular Therapy.
- Saade, D., Bhurucha-Goebel, D., Foley, A.R., Neuhaus, S.B., Soldatos, A., Hu, Y., Hewitt, M., Calcedo del Hoyo, R., Jacobson, S., and Liebovitch, E. (2018). Review of CSF and Peripheral Immune Responses Following Intrathecal Gene Transfer for Giant Axonal Neuropathy, Cell Press. Molecular Therapy.
- Bharucha-Goebel, D., Saade, D., Soldatos, A., Kang, E., Del Calcedo, R., Hu, Y., Liebovitch, E., Jacobson, S., Rybin, D., and Foley, A.R. (2019). Immune Analysis Following Intrathecal Gene Transfer: 3-Year Data from Clinical Intrathecal Gene Transfer Trial for Patients with Giant Axonal Neuropathy, Cell Press. Molecular Therapy.
- Kuntz, N., Shieh, P.B., Smith, B., Bonnemann, C.G., Dowling, J.J., Lawson, M.W., Muller-Felber, W., Noursalehi, M., Rico, S., and Servais, L. (2018). Aspiro Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (Xlmtm): Preliminary Safety and Efficacy Findings, Cell Press. Molecular Therapy.
- (2020, January 28). Pfizer Presents Initial Clinical Data on Phase 1B Gene Therapy Study for Duchenne Muscular Dystrophy (DMD). Available online: https://investors.pfizer.com/investor-news/press-release-details/2019/Pfizer-Presents-Initial-Clinical-Data-on-Phase-1b-Gene-Therapy-Study-for-Duchenne-Muscular-Dystrophy-DMD/default.aspx.
Cited by
Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology
Hordeaux, J., Buza, E. L., Dyer, C., Goode, T., Mitchell, T. W., Richman, L., Denton, N., Hinderer, C., Katz, N., Schmid, R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.167 · Cited by 257
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Durability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
“Mutation status may affect the risk of an immune response, given that those with null mutations (cross-reactive immunological material [CRIM] negative) are more likely to recognize the transgenic protein as foreign and develop more severe antibody andT cell responses than individualswho express the endogenous protein…”
BackgroundNovel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
“…combined with other technologies, such as rational design-based modification of immunogenic residues at the capsid surface or optimisation of the 12 of 19 EMBO Molecular Medicine 13: e13392 | 2021 ª 2021 The Authors AAV2 genome in order to mitigate any risk of immune responses (Perez et al, 2020).”
Metadata
- Authors
- Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M.
- Affiliations
- University of Florida (US)
- AavantiBio, Inc., Gainesville, FL 32601, USA
- Harvard University (US)
- Corresponding author
- Corti, Manuela
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2020-02-22
- Volume
- 10
- Issue
- 2
- Pages
- 119
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC7071492
- OpenAlex
- W3007981561
- Cited by
- 112
- References
- 92
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 14 · 2022: 29 · 2021: 21 · 2020: 7
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (5T32DK074367-04)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, AAV gene therapy, neuroinflammation, neurodegenerative diseases, spinal muscular atrophy, Canavan disease, Parkinson's disease, Friedreich's ataxia, immunosuppression, dorsal root ganglia, myelopathy, mononuclear cell infiltration, neuroinflammation biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases. https://app.cochat.ai/papers/10.3390/brainsci10020119
- The paper
- Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M. (2020). Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases. Brain Sciences. https://doi.org/10.3390/brainsci10020119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.